CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 CAR 的免疫治疗的新型细胞来源
英文原题：New cell sources for CAR-based immunotherapy.
查看英文原题
New cell sources for CAR-based immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法，即将患者自身的T淋巴细胞进行工程化改造以识别并杀伤癌细胞，已在某些血液系统恶性肿瘤的临床前和临床试验中取得了显著成功，目前已有六种FDA批准的CAR-T 产品上市。尽管临床结果令人瞩目，但关于CAR-T 细胞疗效低或细胞毒性高导致治疗失败的担忧仍然存在。虽然主要关注点一直在于改进CAR-T 细胞，但探索用于CAR生成的替代细胞来源已引起越来越多的兴趣。在本综述中，我们全面评估了除常规T细胞以外的其他细胞来源用于CAR生成。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market.
Despite impressive clinical outcomes, concerns about treatment failure associated with low efficacy or high cytotoxicity of CAR-T cells remain. While the main focus has been on improving CAR-T cells, exploring alternative cellular sources for CAR generation has garnered growing interest. In the current review, we comprehensively evaluated other cell sources rather than conventional T cells for CAR generation.
论文信息
- 作者
- Mazinani M、Rahbarizadeh F
- 第一作者单位
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran.Iran
- 通讯作者单位
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran. rahbarif@modares.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- Biomarker research2023 May 6
- 原文标识
- PubMed 37147740 · DOI 10.1186/s40364-023-00482-9
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →